Delving into the Latest Updates on Haemophilus influenzae Type b conjugate Vaccine(Beijing Luzhu Biopharma) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Conjugated vaccine

Synonyms

B型流感嗜血杆菌结合疫苗（智飞生物）, Haemophilus Influenzae Type b Conjugate Vaccine, 喜菲贝

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesNervous System DiseasesOtorhinolaryngologic Diseases+ [3]

Active Indication

Haemophilus InfectionsArthritisCellulitis+ [3]

Inactive Indication-

Originator Organization

Beijing Luzhu Biopharmaceutical Co., Ltd.

Active Organization

Beijing Luzhu Biopharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (31 Dec 2011),

Haemophilus Infections

Regulation-

Login to view timeline

We assessed the safety of hexavalent vaccine diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, hepatitis b, and haemophilus influenzae b conjugate vaccine in the Vaccine Adverse Event Reporting System. Five hundred-one reports of adverse events (AEs) were identified; 21 (4.2%) were serious. Most frequently reported AEs were fever (10.2%) and injection site erythema (5.4%). AEs reported were consistent with findings from prelicensure studies.

01 Jan 2023·Access microbiology

Epidemiology of Haemophilus influenzae in children on Lombok Island, Indonesia.

Article

Author: Safari, Dodi ; Prayitno, Ari ; Aprianti, Shindy Claudya ; Krisna, Made Ananda ; Salsabila, Korrie ; Putri, Nina Dwi ; Paramaiswari, Wisiva Tofriska

The Haemophilus influenzae serotype b (Hib) conjugate vaccine routine immunization programme has been implemented for almost a decade; however, there is limited surveillance of H. influenzae carriage rates in the Indonesian population. H. influenzae was isolated from nasopharyngeal (NP) swab specimens of healthy children on Lombok Island, West Nusa Tenggara Province, Indonesia from 2018 to 2019. Serotyping was performed using quantitative polymerase chain reaction. We identified H. influenzae in 40 of the 96 (41.6 %) NP swab specimens. We identified 39 non-typeable H. influenzae (NTHi) isolates and 1 Hib isolate.

10 Nov 2022·Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

[Five-year immunity persistence following immunization with haemophilus influenzae type b conjugate vaccine].

Article

Author: Wei, M W ; Zhu, J H ; Zhu, F C ; Li, J X ; Chu, K

Objective: To evaluate the immunity persistence five years later after immunization with Haemophilus influenzae type b (Hib) conjugate vaccine in healthy infants/children aged 3 months to 5 years in China. Methods: The children were subjects who completed the whole-schedule immunization in the phase Ⅲ clinical trial in Lianshui county of Jiangsu povince was selected for the collection of blood samples at 5 years after vaccination from November to December, 2019. The enzyme-linked immunosorbent assay (ELISA) was used to detect Hib polyribosyl-ribitol-phosphate antibody (anti-Hib-PRP), and the long-term/short-term protection rate, geometric mean concentration (GMC) and geometric mean concentration increase fold (GMFI) of serum anti-Hib-PRP were calculated. Results: A total of 580 children were enrolled in this study, of which 158, 207 and 215 belonged to 3-5 month age group, 6-11 month age group and 1-5 year age group, respectively. The short-term (≥0.15 μg/ml)/long-term (≥1.0 μg/ml) protection rates of serum anti-PRP in the three groups after immunization were 89.24%, 90.34% and 98.60%, respectively; the GMC were 3.95 μg/ml, 3.11 μg/ml and 10.01 μg/ml respectively, and the GMFI were 29.04, 11.01 and 3.26 respectively. Conclusions: Hib conjugate vaccine can still have good immunogenicity after 5 years of primary immunization in healthy infants/children aged 3 months to 5 years in China.

100 Deals associated with Haemophilus influenzae Type b conjugate Vaccine(Beijing Luzhu Biopharma)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Haemophilus influenzae Type b conjugate Vaccine(Beijing Luzhu Biopharma)	J07AG01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Haemophilus Infections	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	31 Dec 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthritis	Phase 1	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	27 Nov 2019
Cellulitis	Phase 1	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	27 Nov 2019
Epiglottitis	Phase 1	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	27 Nov 2019
Meningitis	Phase 1	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	27 Nov 2019
Pneumonia	Phase 1	CN	Beijing Luzhu Biopharmaceutical Co., Ltd.	27 Nov 2019